CORT vs. SUPN, TARO, AXSM, XNCR, PCRX, OPK, PRGO, ADCT, AVIR, and JAZZ
Should you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Axsome Therapeutics (AXSM), Xencor (XNCR), Pacira BioSciences (PCRX), OPKO Health (OPK), Perrigo (PRGO), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "medical" sector.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.
Corcept Therapeutics received 53 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 70.62% of users gave Corcept Therapeutics an outperform vote.
In the previous week, Corcept Therapeutics had 17 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 23 mentions for Corcept Therapeutics and 6 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.82 beat Corcept Therapeutics' score of 0.24 indicating that Corcept Therapeutics is being referred to more favorably in the news media.
Supernus Pharmaceuticals presently has a consensus price target of $41.00, indicating a potential upside of 32.99%. Corcept Therapeutics has a consensus price target of $40.10, indicating a potential upside of 63.54%. Given Supernus Pharmaceuticals' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.
Supernus Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.
Corcept Therapeutics has lower revenue, but higher earnings than Supernus Pharmaceuticals.
93.6% of Corcept Therapeutics shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Corcept Therapeutics has a net margin of 22.38% compared to Corcept Therapeutics' net margin of 0.22%. Supernus Pharmaceuticals' return on equity of 24.19% beat Corcept Therapeutics' return on equity.
Summary
Corcept Therapeutics beats Supernus Pharmaceuticals on 12 of the 15 factors compared between the two stocks.
Get Corcept Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corcept Therapeutics Competitors List
Related Companies and Tools
